Martin Worley Group Makes New $369,000 Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Martin Worley Group purchased a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $369,000.

A number of other hedge funds also recently made changes to their positions in the business. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals in the fourth quarter worth about $25,000. CoreFirst Bank & Trust acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth $28,000. Allianz SE bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $29,000. Jones Financial Companies Lllp boosted its stake in shares of Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after purchasing an additional 130 shares in the last quarter. Finally, UMB Bank n.a. grew its holdings in shares of Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 129 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Buying and Selling

In other news, CMO Robert Iannone sold 2,403 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $138.41, for a total transaction of $332,599.23. Following the completion of the sale, the chief marketing officer now owns 79,621 shares of the company’s stock, valued at $11,020,342.61. This represents a 2.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Patricia Carr sold 1,140 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the sale, the chief accounting officer now directly owns 7,012 shares in the company, valued at $966,323.72. This represents a 13.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 27,236 shares of company stock valued at $3,837,680. 4.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Barclays restated an “overweight” rating and issued a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Royal Bank of Canada dropped their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Morgan Stanley reaffirmed an “overweight” rating and issued a $183.00 price target (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Finally, Piper Sandler reiterated an “overweight” rating and set a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $187.71.

Jazz Pharmaceuticals Stock Up 1.2 %

NASDAQ:JAZZ opened at $126.44 on Thursday. The stock has a market cap of $7.68 billion, a price-to-earnings ratio of 17.81, a PEG ratio of 1.04 and a beta of 0.44. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a 50-day moving average price of $132.54 and a two-hundred day moving average price of $122.92. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.